Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans

GeroScience, Год журнала: 2021, Номер 43(5), С. 2321 - 2331

Опубликована: Окт. 1, 2021

Abstract In the present study, humoral and T cell-mediated immune responses elicited by BBIBP-CorV (inactivated virus) BNT162b2 (mRNA-based) vaccines against SARS-CoV-2 virus were compared. Convalescent volunteers also investigated to evaluate adaptive immunity induced live virus. Although both antibody- responses, our analysis revealed significant quantitative qualitative differences between two types of challenges. The vaccine antireceptor-binding domain (RBD) IgG, as well anti-spike protein (S) IgG IgA antibodies in healthy individuals, levels which much lower than after vaccination but still higher convalescent patients. cumulative IFNγ-positive cell response, however, was only twofold participants injected with compared those who primed boosted vaccine. Moreover, inactivated response that targets not S nucleocapsid (N) membrane (M) proteins, whereas mRNA able elicit a narrower epitopes only. Thus, pattern BBIBP-CorV-induced virus-naive similar anti-SARS-CoV-2 observed Based on these data, we can conclude is immunologically effective. However, duration integrated, antibody, cell-mediated, needs further investigation.

Язык: Английский

---

Delivering Pandemic Vaccines in 100 Days — What Will It Take?

New England Journal of Medicine, Год журнала: 2022, Номер 387(2)

Опубликована: Март 2, 2022

Язык: Английский

---

Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines

Frontiers in Immunology, Год журнала: 2022, Номер 13

Опубликована: Июнь 21, 2022

In an ongoing multinational trial, we obtained blood samples from 365 volunteers vaccinated with mRNA vaccines (Moderna, BioNTech), viral DNA-vectored (AstraZeneca, Sputnik-V, and Johnson Johnson), or the attenuated virus vaccine Sinopharm. After collecting reactogenicity data, expression of S-Protein binding IgG IgA was analyzed using automated sandwich ELISA system. Serum neutralizing potentials were then investigated ACE-2-RBD assay. Moderna's induced highest amounts SARS-CoV-2 specific antibodies compared to other groups. contrast, Sinopharm Johnson's vaccinees presented lowest SARS-CoV-2-specific antibody titers. Interestingly, moderate high negative correlations between age virus-specific observed in (ρ =-0.3936) =-0.6977) groups according Spearman's rank correlation analysis. A seen Sputnik-V group =-0.3917). The analysis neutralization categories demonstrated that no significant potential older (61and 80 years old) vaccinees' sera Moderna, BioNTech, AstraZeneca statistically comparable all categories. Furthermore, while alone expression, combination Moderna BioNTech significantly higher levels than a double dose similar used alone. These results suggest are most immunogenic after two doses. DNA vectored lower but properties vaccinees. Especially elderly over 60 increase vaccination. data also indicate heterologous vaccination strategies combining more effective induction their homologous counterparts.

Язык: Английский

---

Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines

Mucosal Immunology, Год журнала: 2022, Номер 15(4), С. 584 - 594

Опубликована: Апрель 1, 2022

The development and deployment of vaccines against COVID-19 demonstrated major successes in providing immunity preventing severe disease death. Yet SARS-CoV-2 evolves vaccine-induced protection wanes, meaning progress vaccination strategies is upmost importance. New directed at emerging viral strains are being developed while schemes with booster doses combinations different platform-based tested trials real-world settings. Despite these diverse approaches, only delivered intramuscularly, whereas the nasal mucosa primary site infection SARS-CoV-2. Preclinical mucosal intranasal or oral administration demonstrate promising results regarding IgA generation tissue-resident lymphocyte responses By mounting an improved local humoral cell-mediated response, could be a safe effective way to prevent infection, block transmission contribute reduce spread. However, questions limitations remain: how effectively reproducibly will penetrate barriers? Will provide sustained infection?

Язык: Английский

---

Is vaccine confidence an unexpected victim of the COVID-19 pandemic?

Vaccine, Год журнала: 2022, Номер 40(50), С. 7262 - 7269

Опубликована: Окт. 31, 2022

Vaccines are among the safest and most effective primary prevention measures. Thanks to synergistic global efforts of research institutions, pharmaceutical companies national health services, COVID-19 vaccination campaigns were successfully rolled out less than a year after start pandemic. While unprecedented speed development approval vaccines has been applauded as public success story, it also spurred considerable controversy hesitancy even amongst individuals that did not previously hold anti-vaccination stances. This study aimed compare pre- post-pandemic vaccine confidence trends in different demographic groups by analysing outcomes two online surveys run respectively November 2019 January 2022 involving total 1009 participants. Non-parametric tests highlighted statistically significant decline cohort compared cohort, with median Vaccine Confidence Score dropping from 22 20 23.8% participants reporting their had declined since onset majority internal comparable between regards gender, graduate status religious belief, patterns showed alterations age ethnicity. Middle-aged considerably more hesitant younger however this was case survey. In both White significantly higher those Black backgrounds; unlike pre-pandemic group, Asian lower ones. suggests paradoxically, despite campaigns, pandemic; comparison sheds light on differential effect pandemic groups.

Язык: Английский

---

Pandemic Preparedness and Response: Lessons From COVID-19

The Journal of Infectious Diseases, Год журнала: 2023, Номер 228(4), С. 422 - 425

Опубликована: Апрель 10, 2023

The global experience with COVID-19 holds important lessons for preparing for, and responding to, future emergences of pathogens pandemic potential.

Язык: Английский

---

In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms

Cellular and Molecular Immunology, Год журнала: 2023, Номер 21(2), С. 103 - 118

Опубликована: Дек. 26, 2023

Abstract Members of the coronaviridae family are endemic to human populations and have caused several epidemics pandemics in recent history. In this review, we will discuss feasibility progress toward ultimate goal creating a pan-coronavirus vaccine that can protect against infection disease by all members coronavirus family. We detail unmet clinical need associated with continued transmission SARS-CoV-2, MERS-CoV four seasonal coronaviruses (HCoV-OC43, NL63, HKU1 229E) humans potential for future zoonotic coronaviruses. highlight how first-generation SARS-CoV-2 vaccines natural history studies greatly increased our understanding effective antiviral immunity informed next-generation design. then consider ideal properties propose blueprint type may offer cross-protection. Finally, describe subset diverse technologies novel approaches being pursued developing broadly or universally protective

Язык: Английский

---

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Drugs, Год журнала: 2024, Номер 84(4), С. 403 - 423

Опубликована: Апрель 1, 2024

Язык: Английский

---

Safety and Immunogenicity of a Modified Self-Amplifying Ribonucleic Acid (saRNA) Vaccine Encoding SARS-CoV-2 Spike Glycoprotein in SARS-CoV-2 Seronegative and Seropositive Ugandan Individuals

Опубликована: Янв. 1, 2025

Язык: Английский

---

A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease

medRxiv (Cold Spring Harbor Laboratory), Год журнала: 2021, Номер unknown

Опубликована: Сен. 25, 2021

ABSTRACT Billions of doses COVID-19 vaccines have been administered globally, dramatically reducing SARS-CoV-2 incidence and severity in some settings. Many studies suggest provide a high degree protection against infection disease, but precise estimates vary differ design, outcomes measured, dosing regime, location, circulating virus strains. Here we conduct systematic review through February 2022. We included efficacy data from Phase 3 clinical trials for 15 undergoing WHO Emergency Use Listing evaluation real-world effectiveness 8 with observational meeting inclusion criteria. Vaccine metrics collected include asymptomatic infection, any symptomatic COVID-19, severe including hospitalization death, partial or complete vaccination, variants concern Alpha, Beta, Gamma, Delta, Omicron. additionally the epidemiological principles behind design interpretation vaccine studies, important sources heterogeneity.

Язык: Английский

---